$2.62
-0.05 (-1.87%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RADX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCNCT07259213Incidence of treatment emergent adverse events of 161Tb RAD402 (phase 1) (Safety)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: 161Tb RAD402 | Castration-resistant Prostate Cancer | 73 | 2028-11-30 | in 834 d | 2026-04-01 |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs)Open-label · Treatment | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | Dec 2027 | ≤ 499 d | 2026-02-19 |
| HEAT Trial (HER2 Antibody Therapy With Lutetium-177)NCT06824155Time Activity Curves (TACs)Open-label · Treatment | Early Phase 1 | Recruiting | Drug: 177Lu-RAD202 | HER2 Gene Mutation, Advanced Solid Tumors | 30 | Dec 2027 | ≤ 499 d | 2026-02-11 |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | Dec 2027 | ≤ 499 d | 2026-03-27 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403Open-label · Diagnostic | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2027-08-30 | in 376 d | 2026-08-12 |
| Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301Open-label · Diagnostic | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | Aug 2026 | ≤ 12 d | 2026-07-17 |
| Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumOpen-label · Diagnostic | Phase 2 | Active, not recruiting | Drug: RAD101 (18F-FPIA) | Brain Metastases From Solid Tumors | 30 | 2026-04-23actual | — | 2026-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19